Tofacitinib oral - Biora Therapeutics
Alternative Names: BT-600; PGN-600Latest Information Update: 19 Aug 2024
At a glance
- Originator Progenity
- Developer Biora Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ulcerative colitis
Most Recent Events
- 12 Aug 2024 Biora Therapeutics completes a phase I trial in Ulcerative colitis (In volunteers) in USA (PO) (NCT06275464)
- 12 Aug 2024 Biora Therapeutics plans a phase Ib study for Ulcerative colitis in the end of 2024 (PO)
- 18 Jul 2024 Adverse event data from a phase I trial in Ulcerative colitis released by Biora Therapeutics